AquaBounty Technologies, Inc.

AquaBounty Technologies, Inc., a biotechnology company, focuses on enhancing productivity in the commercial aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It offers AquAdvantage Salmon, a bioengineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Maynard, Massachusetts.

AquaBounty Technologies, Inc. trades as AQB on NASDAQ. The company is classified in Consumer Defensive / Agricultural Farm Products and reports in USD.

The current profile places the business in Agricultural Farm Products. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $0 of revenue and -$18.49M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

AquaBounty Technologies, Inc. can be compared against peers such as AgriFORCE Growing Systems Ltd., Amaze Holdings, Inc., Edible Garden AG Incorporated, Elite Education Group International Limited, Greenlane Holdings, Inc., Golden Sun Education Group Limited.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $3.80M, beta of 1.40, and return on equity of +977.9%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

AQB currently shows total debt of $3.49M and beta of 1.40. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: SC 13G (2026-05-21 00:00:00), 10-Q (2026-05-07 00:00:00), ARS (2026-05-05 00:00:00), DEFA14A (2026-05-01 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.aquabounty.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.